Multiple Myeloma Research Consortium (MMRC) Initiates Phase Ib/II Clinical Trial of Treanda® in Combination with Revlimid® and Dexamethasone in Patients with Relapsed Multiple Myeloma
April 06, 2010 08:16 AM Eastern Daylight Time
First Clinical Trial Launched Using Innovative Platform Designed to Enhance Investigator-Led Studies in the MMRC
NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase...
SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL. Rituxan is administered with two other chemotherapy drugs,...
Bendamustine treatment demonstrated better overall response rate and PFS than chlorambucil treatment in previously untreated patients with advanced CLL.
Researchers conducted a phase-3 multicenter study and randomly assigned 319 patients IV bendamustine (Treanda, Cephalon) 100 mg/m2 per day on days one to two, or chlorambucil (Leukeran, Smithkline Beecham) 0.8 mg/kg orally on days one and 15. Every four weeks, treatment cycles were repeated...
New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas
NCCN presented new NCCN Clinical Practice Guidelines in Oncology(TM) for Primary Cutaneous B-Cell Lymphoma as well as important updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas at the NCCN 14th Annual Conference. The new NCCN Guidelines were written to distinguish Primary B-Cell Lymphomas from their nodal counterparts and provide clinicians with treatment recommendations....
